MANAGEMENT
CONSULTING AGREEMENT
THIS MANAGEMENT
CONSULTING AGREEMENT (the "Agreement") is entered into as of
April 1, 2009 (the “Effective Date”).
NEUROKINE
PHARMACEUTICALS INC.
a corporation
incorporated under the laws of British Columbia having its
principal place of business at 1275 West 6th Avenue, Vancouver,
British Columbia V6H 1A6
AND:
an attorney and
businessperson having her principal place of business at 925 West
Georgia Street, Suite 1820, Vancouver, British Columbia V6C
3L2
WHEREAS:
|
|
The Company is
engaged in the research, development and commercialization of
pharmaceutical products; and
|
|
|
The Company
wishes to engage the services of the Consultant as Vice-President,
Finance, of the Company.
|
THIS AGREEMENT
WITNESSES that in consideration of the premises and mutual
covenants contained in this Agreement and other good and valuable
consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties, intending to be legally bound, hereby
agree as follows:
|
|
ENGAGEMENT AND
APPOINTMENT
|
|
|
The Company
hereby engages and appoints the Consultant to serve as the
Vice-President, Finance, of the Company and to provide the Services
(as defined below) in accordance with and subject to the terms and
conditions of this Agreement and the Consultant hereby accepts such
engagement and appointment
|
|
|
The appointment
of the Consultant as Vice-President, Finance, under this Agreement
shall be subject to the provisions of the Articles of the Company
regarding the appointment, compensation, indemnification,
disqualification and removal of officers.
|
|
|
The Term of
this Agreement shall be for an initial period of one (1) year
commencing on the Effective Date and ending 12 months thereafter
unless earlier terminated in accordance with section 7 (the “
Term ”).
|
|
|
In
consideration of the compensation payable in accordance with
section 5, the Consultant hereby agrees to use her best efforts to
perform or cause to be performed the following services:
|
|
|
|
assisting the
Company to develop and manage the execution of its business
plan;
|
|
|
|
overseeing and
performing all services reasonably required to publicly list the
common stock of the Company on the Over the Counter Bulletin Board
(“ OTCBB ”), including the following
work:
|
|
|
|
overseeing the
engagement of an auditor for the Company;
|
|
|
|
communicating
with the accountants and auditor of the Company to facilitate the
preparation of financial statements;
|
|
|
|
securing a
market maker for the Company;
|
|
|
|
engaging a
transfer agent for the Company;
|
|
|
|
soliciting and
securing a minimum of 33 investors for the Company in order to
complete the Company’s OTCBB listing; and
|
|
|
|
overseeing the
preparation of a registration statement on Form S-1 for the
Company;
|
|
|
|
introducing the
Company to broker/dealers; and
|
|
|
|
overseeing and
performing all corporate finance work for the Company during the
Term, including, but not limited to, due diligence and
the negotiation and preparation of financing
agreements.
|
(collectively,
the “Services”)
|
|
The Consultant
shall devote as much time, attention and energy to the business and
affairs of the Company as may be reasonably necessary to perform
the Services.
|
|
4.
|
RELATIONSHIP
AMONG THE PARTIES
|
|
|
Nothing
contained in this Agreement shall be construed to (i) constitute
the parties as joint venturers, partners, co-owners or otherwise as
participants in a joint undertaking; (ii) constitute the Consultant
as an employee of the Company; or (iii) authorize or permit the
Consultant or any director, officer, employee, agent or other
person acting on its behalf to incur any obligation of any kind,
either express or implied, or do, sign or execute any things,
deeds, or documents which may have the effect of legally binding or
obligating the Company in any manner in favour of any individual,
business, trust, unincorporated association, corporation,
partnership, joint venture, limited liability company or other
entity of any kind. The Company and the Consultant agree
that the relationship among the parties shall be that of
independent contractor.
|
|
|
In full
consideration of the Services, the Company shall issue to the
Consultant 192,000 common shares of the Company’s capital
stock at a rate of 16,000 per month throughout the Term, payable in
four installments of 48,000 shares at the conclusion of each 3
month period during the Term. Each issuance of shares by
the Company to the Consultant under this Agreement shall be subject
to the terms of the subscription agreement in the form attached
hereto as Schedule “A’. The shares shall
issued by the Company to the Consultant hereunder shall be assessed
at their fair market value at the time of issuance.
|
|
6.
|
SERVICES NOT
EXCLUSIVE
|
|
|
The Company
acknowledges that Consultant is engaged in other business and
professional activities and the Consultant shall not be restricted
from engaging in such activities during the term of this
Agreement.
|
|
7.
|
SUSPENSION AND
TERMINATION.
|
|
|
Termination for
Cause by Company . The
Company may terminate this Agreement for cause at any time and
without notice in the event the Consultant engages in any
negligence, dishonesty, fraud, insubordination, serious misconduct
or anything else that would constitute cause at law. The failure by
the Company to rely on this provision in any given instance or
instances shall not constitute a precedent or be deemed a
waiver.
|
|
|
Termination for
Cause by Consultant . The
Consultant may terminate this Agreement for cause at any time
without notice in the event the Company engages in any negligence,
dishonesty, fraud, insubordination, material misrepresentation,
serious misconduct or anything else that would constitute cause at
law. The failure by the Consultant to rely on this provision in any
given instance or instances shall not constitute a precedent or be
deemed a waiver. The Consultant shall also be entitled
to terminate this Agreement in the event of the Company’s
insolvency, voluntary or involuntary bankruptcy, receivership or
assignment for the benefit of creditors.
|
|
|
Force
Majeure . The
parties shall have the right to suspend this Agreement in the event
of force majeure at any time, provided the Company provides prompt
written notice of such suspension to the Consultant. The
suspension of this Agreement shall not relieve either party of
their obligations hereunder. The Company and the
Consultant shall each have the right to terminate this Agreement by
giving written notice to the other party where an event or events
of force majeure continues for a continuous period of 20
consecutive business days or 30 days in the aggregate during the
Term.
|
|
|
Effect of
Termination . Upon
any termination in accordance with this Agreement, all obligations
of the parties shall cease provided that the Consultant shall be
entitled to receive any compensation accrued prior to the effective
date of such termination. Notwithstanding the foregoing,
the provisions of sections 8 and 9 shall survive the termination of
this Agreement.
|
|
|
The Consultant
shall not, without the prior authorization of the Company, at any
time during the Term or thereafter, disclose to any person, firm,
association or corporation other than the directors, officers or
employees of the Company, the private or business affairs of the
Company or its affiliated companies, or any other information of a
private or confidential nature concerning the Company or its
affiliated companies (the “ Confidential
Information ”) including, without
limitation:
|
|
|
|
information
concerning trade secrets, products, technology, sales literature
and brochures, forms, business policies and concepts, and contracts
of the Company;
|
|
|
|
information
concerning manufacturing and production, pricing and sales
policies, and marketing techniques and concepts in respect of
products and services provided or to be provided by the
Company;
|
|
|
|
names,
addresses and contact information of past, present or prospective
customers, employees, shareholders, officers, directors or
associates of the company, or any person or entity having a past,
present, or prospective business relationship with the Company,
and
|
|
|
|
names,
addresses and contact information of past, present or prospective
suppliers, consultants, lenders or professional advisors of the
Company and prices or rates charged by them;
|
which by virtue
of the Consultant’s position, the Consultant may obtain
during the Term.
|
|
The Consultant
acknowledges that the Confidential Information could be used to the
detriment of the Company. Accordingly the Consultant
undertakes to treat confidentially all such information and agrees
not to disclose any Confidential Information to any third party or
use it for any purpose or reason without the express written
permission of the Company, except as may be necessary to perform
its duties, whether during the Term or thereafter.
|
|
|
For the
purposes of this Agreement, Confidential Information shall not
include any information which the Consultant can prove by competent
evidence, is:
|
|
|
|
now, or
hereafter becomes, through no act or failure to act on the part of
the Consultant, generally known or available to the
public;
|
|
|
|
known by the
Consultant at the time of receiving such information, as evidenced
by its records;
|
|
|
|
hereafter
furnished to the Consultant without restriction as to disclosure or
used by a third party lawfully entitled to furnish such
information;
|
|
|
|
independently
developed by the employees, agents or contractors of the Consultant
without the aid, application or use of the Confidential
Information; or
|
|
|
|
the subject of
a written permission to disclose provided by the
Company.
|
|
9.
|
REPRESENTATIONS
AND WARRANTIES
|
|
|
The Consultant
represents, warrants and covenants to the Company that the
Consultant is and will remain, during the Term, qualified and
licensed to practice law in the Province of British Columbia and
the State of Washington.
|
|
|
The Company
agrees to indemnify and hold harmless the Consultant and its
respective agents and employees against any losses, claims, damages
or liabilities, joint or several, to which either party, or any
such other person, may become subject, insofar as such losses,
claims, damages or liabilities (or actions, suits or proceedings in
respect thereof) arise out of or are based upon any untrue
statement or alleged untrue statement of any material fact
contained in any registration statement, preliminary prospectus,
prospectus or any amendment or supplement thereto; or arise out of
or are based upon the omission or alleged omission to state therein
a material fact required to be stated therein, or necessary to make
the statements therein not misleading; and shall reimburse the
Consultant, or any such other person, for any legal or other
expenses reasonably incurred by the Consultant, or any such other
person, in connection with investigating or defending any such
loss, claim, damage, liability, or action, suit or
proceeding.
|
|
|
The Consultant
agrees to indemnify and hold harmless the Company, its partners,
financiers, parent, affiliated and related companies and all of
their respective individual shareholders, directors, officers,
employees, licensees and assigns from and against any claims,
actions, losses and expenses (including legal expenses) occasioned
by any breach of the Consultant’s representations and
warranties contained in this Agreement, or by any breach of any
other provision hereof by the Consultant.
|
|
11.
|
MISCELLANEOUS
PROVISIONS
|
|
|
Time
. Time
is of the essence of this Agreement.
|
|
|
Presumption
. This
Agreement or any section thereof shall not be construed against any
party due to the fact that said Agreement or any section thereof
was drafted by said party.
|
|
|
Titles and
Captions . All
article, section and paragraph titles or captions contained in this
Agreement are for convenience only and shall not be deemed part of
the context nor affect the interpretation of this
Agreement.
|
|
|
Further
Action . The
parties hereto shall execute and deliver all documents, provide all
information and take or forbear from all such action as may be
necessary or appropriate to achieve the purposes of this
Agreement.
|
|
|
Good Faith,
Cooperation and Due Diligence . The
parties hereto covenant, warrant and represent to each other good
faith, complete cooperation, due diligence and honesty in fact in
the performance of all obligations of the parties pursuant to this
Agreement. All promises and covenants are mutual and
dependent.
|
|
|
Savings
Clause . If
any provision of this Agreement, or the application of such
provision to any person or circumstance, shall be held invalid, the
remainder of this Agreement, or the application of such provision
to persons or circumstances other than those as to which it is held
invalid, shall not be affected thereby.
|
|
|
Assignment
. This
Agreement may not be assigned by either party hereto without the
written consent of the other party.
|
|
|
Notices
. All
notices required or permitted to be given under this Agreement
shall be given in writing and shall be delivered, either personally
or by express delivery service, to the party to be
notified.
|
|
|
Entire
Agreement . This
Agreement, including Schedule “A”” attached
hereto, contains the entire understanding and agreement between the
parties. There are no other agreements, conditions or
representations, oral or written, express or implied, with regard
thereto.
|
|
|
Amendment
. This
Agreement may only be amended in writing signed by the parties
hereto.
|
|
|
Waiver
. A
delay or failure by any party to exercise a right under this
Agreement, or a partial or single exercise of that right, shall not
constitute a waiver of that or any other right.
|
|
|
Counterparts
. This
Agreement may be executed in counterparts, each of which shall be
deemed an original, but all of which together shall constitute one
and the same Agreement. In the event that this Agreement
is signed by one party and faxed to another, the parties agree that
a faxed signature shall be binding upon the parties as though the
signature was an original.
|
|
|
Successors
. The
provisions of this Agreement shall be binding upon the parties,
their successors and permitted assigns.
|
|
|
Governing
Law. This Agreement
shall be governed by and construed in accordance with the laws of
the Province of British Columbia, Canada and the laws of Canada
applicable therein. The parties hereby attorn the
exclusive jurisdiction of the provincial and federal courts located
in the city of Vancouver, British Columbia in relation to all
disputes arising from this Agreement.
|
|
|
Counsel
. The
parties expressly acknowledge that each has been advised to seek
separate counsel for advice in this matter and has been given a
reasonable opportunity to do so.
|
IN WITNESS
WHEREOF the parties have executed this Agreement as of the date
first written above.
NEUROKINE
PHARMACEUTICALS INC.
Per:
/s/ Ahmad
Doroudian
Ahmad
Doroudian
President
and Chief Executive
Officer
PENNY
GREEN
/s/ Penny
Green
Penny
Green
SCHEDULE
“A”
NEUROKINE
PHARMACEUTICALS INC.
SUBSCRIPTION
AGREEMENT
(THE
“AGREEMENT”)
The undersigned
subscriber (the “Subscriber”) hereby subscribes for and
agrees to purchase 48,000 common shares in the capital stock of
Neurokine Pharmaceuticals Inc. (the “Company”) at a
price of US$ _____________ per share (the
“Shares”) for aggregate proceeds of US$
_____________ (the “Funds”), all on the terms
and subject to the conditions set forth in Exhibit “A”
attached hereto.
|
EXECUTION BY
SUBSCRIBER
|
|
______________________
Tax ID or
Social Insurance Number
|
Penny
Green
Name of
Subscriber
|
|
Provision of
Services
Payment
Method
_____________________________________
Signature of
Individual Subscriber or
Authorized
Signatory of Subscriber
(if Subscriber
not an individual)
_____________________________________
Number and type
of securities of the Company
directly and
indirectly held by Subscriber
|
925 West
Georgia Street, Suite 1820
Vancouver,
British Columbia V6C 3L2
Address of
Subscriber
_____________________________________
Name of Contact
Person, if Subscriber not an individual
(604)
632-1700
Telephone
Number of Subscriber or Contact Person
(604)
632-1730
Facsimile
Number of Subscriber or Contact Person
|
Executed by the
Subscriber this 1st day of April, 2009.
Please complete
the following section if you require the certificate(s)
representing the Shares to appear in the name of an intermediary,
such as your broker, or require the certificate(s) to be delivered
to an address other than that shown above.
|
REGISTRATION
INSTRUCTIONS
|
DELIVERY
INSTRUCTIONS
|
Name to appear
on certificate(s)
|
_____________________________________
Name and
account reference, if applicable
|
_____________________________________
Account
reference, if applicable
|
_____________________________________
|
_____________________________________
_____________________________________
|
_____________________________________
|
ACCEPTED by the
Company this __________ day of ________________,
2009.
NEUROKINE
PHARMACEUTICALS INC.
Per:
/s/ Ahmad Doroudian
Ahmad
Doroudian
President
and Chief Executive Officer
Exhibit
“A” To Subscription Agreement
In
consideration of the covenants and agreements in this Agreement,
and the payment of one dollar made by each party to the other, the
receipt and sufficiency of which is acknowledged by each party, the
parties agree as follows:
Delivery of
Documents and Funds
The Subscriber
hereby delivers to the Company:
|
|
a completed and
executed copy of this Agreement; for all Subscribers: a
completed and executed Investor Exemptions Questionnaire attached
as Exhibit “B” and in the case of a subscription for
the Shares by the Subscriber acting as trustee or agent for a
principal, the Subscriber shall provide the Company with an
Accredited Investor Questionnaire in the form set forth in Exhibit
“B” for each trust, beneficial owner and/or principal
for which the Subscriber is acting as trustee or agent;
|
|
|
if the
Subscriber is a U.S. Person, additionally: a completed and executed
Accredited Investor Questionnaire attached as Exhibit
“C” and in the case of a subscription for the Shares by
the Subscriber acting as trustee or agent for a principal, the
Subscriber shall provide the Company with an Accredited Investor
Questionnaire in the form set forth in Exhibit “C” for
each trust, beneficial owner and/or principal for which the
Subscriber is acting as trustee or agent; and
|
|
|
unless an
alternate payment method has been agreed upon in writing, a
certified check or bank draft for the Funds made payable to
“Neurokine Pharmaceuticals Inc.”.
|
Closing
The closing of
the transactions contemplated by this Agreement (the
“Closing”) will take place within 10 business days of
the receipt of this Agreement by the
Company.
At the Closing,
the Company will deliver to the Subscriber the certificates
representing the Shares and an agreement representing the Shares
purchased by the Subscriber registered in the name of the
Subscriber or as directed on the cover page of this
Agreement.
Subscriber’s
Representations, Warranties, Covenants, Acknowledgements and
Agreements
|
|
The Subscriber
represents and warrants to the Company, and acknowledges that the
Company is relying on these representations and warranties to,
among other things, ensure that it is complying with all of the
applicable securities legislation, that:
|
|
|
|
the Subscriber
is purchasing as principal and is either:
|
|
|
|
not a U.S.
person and is not acquiring the Shares for the account or benefit
of any U.S. person; OR
|
|
|
|
a U.S. person
who is purchasing the Shares in a transaction that does not require
registration under the U.S. Securities Act.
|
|
|
|
if the
Subscriber is a resident of an “International
Jurisdiction” (which means a jurisdiction other than British
Columbia), then:
|
|
|
|
the Subscriber
is knowledgeable of, or has been independently advised as to, the
applicable securities legislation of the International Jurisdiction
which would apply to this subscription, if there are
any;
|
|
|
|
the Subscriber
is purchasing the Shares pursuant to exemptions under the
securities legislation of that International Jurisdiction or, if
such is not applicable, the Subscriber is permitted to purchase the
Shares under the applicable securities legislation of the
International Jurisdiction without the need to rely on exemptions;
and
|
|
|
|
|
|
|
(iii)
|
the applicable
securities legislation does not require the Company to make any
filings or seek any approvals of any kind whatsoever from any
regulatory authority of any kind whatsoever in the International
Jurisdiction; and
|
the Subscriber
will, if requested by the Company, deliver to the Company a
certificate or opinion of loca
|